Viewing Study NCT02826005


Ignite Creation Date: 2025-12-25 @ 3:18 AM
Ignite Modification Date: 2026-03-01 @ 8:11 PM
Study NCT ID: NCT02826005
Status: UNKNOWN
Last Update Posted: 2016-07-12
First Post: 2016-07-04
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.
Sponsor: Ilex Medical
Organization:

Study Overview

Official Title: Examination the Ability to Early Diagnose HCC
Status: UNKNOWN
Status Verified Date: 2016-07
Last Known Status: ENROLLING_BY_INVITATION
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Examination the ability to early diagnose HCC by combining three biomarkers technology developed by WAKO, And their relevance to cirrhotic of patients with various backgrounds and the Israeli population.

This blood test will serve as an additional diagnostic tool tools currently in use (Ultrasound and AFP levels) to cirrhotic patients with high risk to develop hepatocellular carcinoma.

Another group that will be examined for all three biomarkers will be patients which already diagnosed with hepatocellular carcinoma, and have normal AFP level in order to examine the correlation between the presence of tumor, the number of them and the tumor size and the three biomarkers concentration in their blood
Detailed Description: None

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: